Keryx Announces Appointment of John P. Butler to its Board of Directors
10 déc. 2015 08h00 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
Keryx Biopharmaceuticals Announces Webcast of Presentation at Oppenheimer's 26th Annual Healthcare Conference
01 déc. 2015 09h05 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
Keryx Biopharmaceuticals Announces Participation at Two Upcoming Investor Conferences
03 nov. 2015 16h05 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 03, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
Keryx Biopharmaceuticals Announces Third Quarter 2015 Financial Results
29 oct. 2015 07h00 HE
|
Keryx Biopharmaceuticals, Inc.
– Growth in third quarter Auryxia™ (ferric citrate) product sales driven by increased breadth and depth of prescribers – – Keryx well positioned with strengthened cash position to support Auryxia...
Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2015 Financial Results on Thursday, October 29, 2015
21 oct. 2015 09h05 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
Keryx Biopharmaceuticals Announces $125 Million Private Placement of Convertible Senior Notes With The Baupost Group, L.L.C.
15 oct. 2015 07h00 HE
|
Keryx Biopharmaceuticals, Inc.
Keryx implements plan to significantly reduce its annual cash operating expenses, beginning in 2016Increased cash position expected to take Auryxia™ (ferric citrate) franchise to cash flow positive ...
Keryx Receives European Approval for Fexeric(R) (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease
24 sept. 2015 07h00 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that the European Commission has approved Fexeric® (ferric citrate coordination complex)...
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
09 sept. 2015 08h30 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease,...
Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results
05 août 2015 07h00 HE
|
Keryx Biopharmaceuticals, Inc.
Majority of phosphate binder patients today have access to Auryxia™
CHMP recently adopted a positive opinion for Fexeric® (ferric citrate coordination complex) in the EU
Enrollment...
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2015 Financial Results on Wednesday, August 5, 2015
28 juil. 2015 16h05 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, July 28, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease,...